Book Volume 10
Page: i-i (1)
Page: ii-iii (2)
Page: 1-23 (23)
Author: Mohammad Hassan Houshdar Tehrani*
PDF Price: $15
Cancer diseases affecting many organs of human body have caused a major concern among the people all over the world. The conventional anticancer drugs, although have given some relief in the patient conditions, still cannot provide reliable treatment. Moreover, these drugs produce side effects in patients and in the worse cases, the problem of rising resistance phenomena against such drugs gradually put the patients’ lives even in more serious situation. Therefore, identifying and introducing compounds with new identities to produce effective treatment with low side effects are highly demanded. Small peptides with anticancer activity have been shown to fulfill this demand. Peptides, with naturally or synthetic origin, have several advantages over common drug molecules such as low toxicity, low immunogenicity, amenable to several changes in their sequences and thus giving various homologues or analogues. Moreover, peptides in conjugation with heterocyclic active compounds and/or known anticancer drugs may result in molecules with new identities which show both benefits of individual components within their unit structures. In this regard, peptide conjugates may play a role, not only as anticancer agents but also as cell-membrane penetrating and/ or cell targeting agents to help direct cancerous tissue internalization of the known anticancer agents, and so, preventing or lowering the incidence of side effects of the anticancer drugs on healthy tissues. In this chapter on the basis of several experiments, information about various peptide categories, their analogues and conjugation with other bioactive compounds is given. The discussion is focused on the anticancer activity of peptides, those primarily known for other biological activities. Understanding the cause of these activities may help to find out and make clearer the mechanism of anticancer activity of the peptides.
Studying of the CLL After Treatment Using Fractal Parameter of Neoplastic Lymphocytes Detection (λnld)
Page: 24-34 (11)
Author: Mohammad Reza Rezaei* and Zahra Rostami
PDF Price: $15
Background: Chronic lymphocytic leukemia (CLL) affects lymphoid cells and has a different chronic course. Some patients die due to the rapid progression of disease despite therapeutic measures. Therefore, it is necessary to identify, predict the disease, and seek new therapeutic strategies.
Introduction: Fractal geometry can be introduced as one of the most efficient methods to study the control of CLL in this type of cancer. The present research, presenting an appropriate model for investigating the possibility of CLL control using the fractal parameter.
Method: First, blood samples of the 30 healthy and 30 CLL samples with leukemia undergoing treatment were selected randomly. Second, the digital images were prepared using an optical microscope with a magnification of X100. Next, the fractal dimension of the lymphocyte nucleus of healthy and leukemia undergoing treatment was calculated using fractal software. Finally, the results were analyzed, and the fractal parameter of Neoplastic lymphocytes detection (λnld) was introduced and was calculated.
Result: The probability of CLL development increases with an increase in fractal parameter of Neoplastic lymphocytes detection (λnld). If the λnld value decreases during the CLL treatment, then the CLL was controlled. Full recovery occurs when λnld is smaller than the unit.
Conclusion: The average fractal dimension of the healthy lymphocytes and CLL nucleus and the fractal parameter of Neoplastic lymphocytes detection (λnld) in this research were 1.781992 ± 0.046178, 1.801322 ± 0.042357 and 0.21833 respectively. Because the λnld is smaller than the unit, the full recovery occurs for this therapeutic group
Page: 35-49 (15)
Author: A. Harikrishnan*, B.S. Supreetha and V Veena *
PDF Price: $15
Rhenium-based cancer drugs seem to be alternative drug candidates for platinum-based drugs in the treatment of cancer. Rhenium based anticancer compounds have attracted several researchers due to their various properties and wide-ranging applications as prodrug, drug conjugates, targeted delivery, imaging and cancer killing capacities. An array of rhenium compounds displays promising cytotoxic and phototoxic properties towards cancer cells. Re-complexes with aromatic or heteroaromatic ligands like polypyridine complexes, octahedral and tris (hydroxymethyl) phosphine(THP) have prodrug properties which upon irradiation, exhibits cytotoxicity activities. PentylcarbanatoRe(I) diimine complexes, 2-(acetyloxy) benzoate Re(CO3), Re(CO3) pentylcarbonato complexes, [Re(CO)3(2-amino-4-phenyl amino-6-(2-pyridyl)-1,3,5-triazine)Cl] and Thiophene-2-carbohydrazide Re(V) complexes exhibits strong DNA binding activities. The 2-acetylpyridine-derived hydrazones Re(CO)3, Re(I) polypyridyl complexes and fac-[Re(CO)3(phen)] carboxy lato complexes were conjugated with aspirin reported as anti-inflammatory drugs. OxoRe(V) complexes with 3,3′-thiodipropanethiol tridentate ligands have been reported to inhibit the cathepsin B and K. Similar, Re-based complexes are synthesised using various ligands and that exhibit selectivity, controlled release and high efficacy potentials. However, still this research is at the preclinical studies. Re-based complexes have well-documented for antioxidant, drug delivery, selective anticancer activities, anti-inflammatory, DNA binding and damage inducing potential depending on the type ligand-Re complexes to contribute to cancer therapy. Thus, Re-compounds can be utilised in targeted therapies through coupling them with the biomolecules especially proteins and anticancer drugs. Among them, diselenium-rhenium complexes have selectivity and reduce the stress in the tumor environment to down regulate the breast cancer specific inflammatory cytokines to enhance the anticancer activity. Therefore, rhenium-based drugs are promising drugs candidate other than platinum-based drugs.
Page: 50-67 (18)
Author: V. Veena*, Pravallika Mandlipalli and A Harikrishnan*
PDF Price: $15
Cancer is a complicated family of diseases that causes major hurdles for global health. Several studies on cancer biology and cancer treatment strategies have revealed that cancer is highly genetically diverse and heterogenic in nature. The complexity of cancer is due to the highly inflammatory microenvironment which resembles wound healing process and highly acidic in nature. Hence, this condition is referred as cancer related inflammation (CRI) that drives the cancer resistance and subsequent recurrence of cancer after treatment. The major deregulated pathways associated with CRI are nuclear factor kappa B (NF-κB) and phosphoinositol-3-kinases (PI3-K) involved in cancer growth, proliferation, cancer cell survival and metastasis. Therefore, the protein factors of these pathways seem to be an attractive target for the molecular targetted therapy for cancer. However, efficient cancer treatment relies on the stages of cancer and the response to the treatment. Hence, cancer specific inflammatory components are the major targets for drug discovery, development and associated clinical trials.
Page: 68-99 (32)
Author: Deepa S. Mandlik* and Satish K. Mandlik
PDF Price: $15
One of the most deadly illnesses in the world remains cancer. New drugs with novel modes of action are urgently needed, recently, much work has been done on novel anticancer molecules derived from natural origins, particularly plants, microorganism and marine organisms. Marine natural products are repositories of novel bioactive metabolites containing different classes of bioactive substances and drug leads. This book chapter highlights the influence of marine organisms, with a specific focus on the ocean resources of marine plants, bacteria, algae, fungi, actinomycetes, sponges, soft corals, diatoms and ascidians, calculating above 90% of the overall ocean biomass. The cell lines and preclinical anti-cancerous effects of marine natural products were first introduced; their activity in preventing tumour development and associated compound-induced apoptosis and cytotoxicity was addressed. They are taxonomically distinct, having a high degree of efficiency and novel chemical structures that are pharmacologically active, creating tremendous potential for the progress of new anticancer molecules. These molecules have numerous pharmacological potentials, such as antioxidant, anti-tumour and antibacterial. Several marine anticancer agents have recently been extracted, characterized, described and are currently being studied for a clinical study. In this book chapter, we have attempted to assemble knowledge about the anticancer potential of marine products in a diversity of flora and fauna, as well as their probable mechanism of action. The molecular mechanisms that underpin the biological effects are also discussed. Finally, it addresses therapeutic methods and the present use of drugs extracted from the marine source, its future direction and limitations.
Page: 100-150 (51)
Author: Samad Muhammadnejad, Seyed Mostafa Monzavi, Amir Arsalan Khorsand and Abdol-Mohammad Kajbafzadeh*
PDF Price: $15
Animal models are useful tools for understanding cancer biology and genetics and serve as an essential platform for the preclinical development of anticancer therapeutics. In this context, cancer-bearing patient-derived xenograft (PDX) models, also called cancer avatars, have successfully replaced the traditional cell linederived models in recent years. PDX-based studies are now widely used for preclinical testing of novel treatments as well as tailoring personalized medicine. For anti-cancer research, however, the use of PDX models propagated from a unique patient does not fully represent the true therapeutic efficacy and toxicity of a drug. That is why many studies in this format later failed to show efficacy and safety in human clinical trials. Hence, the concepts of PDX clinical trials and co-clinical trials have gained importance and prospered in recent years. A PDX clinical trial implies investigation on a set of PDXs originated from multiple patients prior to an early phase human trial, whereas a co-clinical trial refers to drug response assays, in parallel and simultaneously with a human clinical trial, on a set of PDX models established from the same clinical trial participants. A carefully designed PDX- /co- clinical trial requires a meticulous calculation of the sample size, enrollment of pathologically and molecularly diverse patients, and selection of suitable endpoints and outcome measures. With a special focus on PDX clinical trial design in anti-cancer research, this chapter specifically addresses how to develop cancer-bearing PDX models, what to consider in characterizing them, how to track their fidelity to the parental tumor, how to estimate the number of animals included in a PDX trial, how to achieve greater power in the translation of final outcomes, what are the minimum endpoints to be considered, and what measures are preferred for evaluating the response to therapeutic interventions.
Page: 151-156 (6)
Topics in Anti-Cancer Research covers new developments in the field of cancer diagnosis and drug therapy. Novel drugs as anticancer agents include natural and synthetic phenazirines and other anti-cancer compounds. The series also covers information on the current understanding of the pathology and molecular biology of specific neoplasms. <p> The diversity of research topics published in this book series give broad and valuable perspectives for cancer researchers, clinicians, cancer professionals aiming to develop novel anti-cancer targets and patents for the treatment of various cancers. <p> The topics covered in this volume are: <p> - Peptides can play a major role in combating cancer diseases <p> - Studying of the CLL after treatment using fractal parameter of neoplastic lymphocytes detection (ΛNLD) <p> - Mechanistic insight of rhenium-based compounds as anti- cancer agents <p> - Targeting cancer-specific inflammatory components in cancer therapeutics <p> - Marine natural products as a source of novel anticancer agents: a treasure from the ocean <p> - PDX clinical trial design in anti-cancer research